Replies to post #450114 on Zeev's Turnips Patch-No Politics (ZEEV)

[snp]

But then the fact still remains that KOSP's drug is the only one in town for the next few years and all that publicity of MRK/PFE trying to get into the HDL space can generate a lot of business for KOS. Also MRK entering into the space is not the same as an entry of a generic drug maker ( that could potentially cause a price crash). As I understand it, MRK is trying a low-flush version of the drug which will enter phase III trials 1Q 2006 and hence is still unproven. Also KOSP patents on the extended release Niacin seem airtight as seen by the BARR settlement.

I think this is just an overreaction by the street that caused KOSP to come down from 72 to where it is now.